Clinical analysis of 81 cases of malignant lymphoma treated with autologous hematopoietic stem cell transplantation.
- Author:
Li WANG
1
;
Lei FAN
1
;
Kourong MIAO
1
;
Ji XU
1
;
Run ZHANG
1
;
Ming HONG
1
;
Huayuan ZHU
1
;
Wenyi SHEN
1
;
Xiaoyan ZHANG
1
;
Lijuan CHEN
1
;
Hongxia QIU
1
;
Hua LU
1
;
Peng LIU
1
;
Hanxin WU
1
;
Wei XU
1
;
Jianyong LI
1
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; therapy; Male; Middle Aged; Retrospective Studies; Transplantation, Autologous
- From: Chinese Journal of Hematology 2014;35(4):328-331
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigated the curative effect of autologous hematopoietic stem cell transplantation (ASCT) for malignant lymphoma.
METHODSThe clinical data of 81 patients with malignant lymphoma received ASCT from April 1999 to October 2013 were retrospectively analyzed. Of 81 patients, 70 were non-Hodgkin's lymphoma (NHL) and 11 Hodgkin's lymphoma (HL). High dose of etoposide combined with G-CSF was used to mobilize peripheral hematopoietic stem cell. Preconditioning regimen was BEAM (carmustine + cytarabine + etoposide + melphalan).
RESULTSEnough peripheral blood stem cells were collected from all patients. All of the patients after transplantation achieved hematopoietic reconstitution, the median time of the absolute neutrophil count (ANC) recovery to >0.5×10⁹/L time was 10(7-16) d, and the median time of platelet count recovery to >20×10⁹/L was 10(6-17) d. With the follow-up of 23(2-139) months, progression free survival (PFS) was 72.7%, and overall survival (OS) was 88.6%. The median PFS and OS were not reached. Complete remission (CR) before ASCT was an independent prognostic factor of PFS. No transplant related death happened.
CONCLUSIONASCT was a safe and effective method for treatment of malignant lymphoma.
